Compare Sysmex Corp. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a 7.13% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Operating profit has grown by an annual rate 7.13% of over the last 5 years
3
The company has declared Negative results for the last 5 consecutive quarters
4
With ROE of 9.32%, it has a expensive valuation with a 1.78 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 975,065 Million (Mid Cap)
19.00
NA
0.00%
-0.09
9.29%
1.93
Revenue and Profits:
Net Sales:
138,838 Million
(Quarterly Results - Mar 2026)
Net Profit:
1,852 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.21%
0%
25.21%
6 Months
10.51%
0%
10.51%
1 Year
-19.1%
0%
-19.1%
2 Years
-35.66%
0%
-35.66%
3 Years
-82.22%
0%
-82.22%
4 Years
-79.96%
0%
-79.96%
5 Years
-87.55%
0%
-87.55%
Sysmex Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.21%
EBIT Growth (5y)
7.13%
EBIT to Interest (avg)
39.04
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.98
Tax Ratio
27.13%
Dividend Payout Ratio
66.79%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
20.40%
ROE (avg)
11.89%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
1.78
EV to EBIT
12.15
EV to EBITDA
7.40
EV to Capital Employed
1.83
EV to Sales
1.70
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
15.09%
ROE (Latest)
9.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 2 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
138,838.00
141,777.00
-2.07%
Operating Profit (PBDIT) excl Other Income
26,805.00
33,711.00
-20.49%
Interest
1,698.00
1,337.00
27.00%
Exceptional Items
-11,557.00
-3,210.00
-260.03%
Consolidate Net Profit
1,852.00
11,079.00
-83.28%
Operating Profit Margin (Excl OI)
109.40%
164.90%
-5.55%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is -2.07% vs 5.03% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -83.28% vs -27.53% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
500,006.00
508,643.00
-1.70%
Operating Profit (PBDIT) excl Other Income
108,606.00
128,708.00
-15.62%
Interest
3,800.00
2,995.00
26.88%
Exceptional Items
-12,115.00
-3,731.00
-224.71%
Consolidate Net Profit
35,374.00
53,576.00
-33.97%
Operating Profit Margin (Excl OI)
124.30%
176.30%
-5.20%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is -1.70% vs 10.21% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -33.97% vs 7.64% in Mar 2025
About Sysmex Corp. 
Sysmex Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






